Piper Sandler Lowers Axon Enterprise (NASDAQ:AXON) Price Target to $690.00

Axon Enterprise (NASDAQ:AXON) had its price target dropped by research analysts at Piper Sandler from $753.00 to $690.00 in a report released on Wednesday, Marketbeat Ratings reports. The brokerage presently has an “overweight” rating on the biotechnology company’s stock. Piper Sandler’s price objective indicates a potential upside of 25.41% from the company’s current price.

A number of other equities research analysts also recently issued reports on the company. Morgan Stanley decreased their price objective on Axon Enterprise from $760.00 to $713.00 and set an “overweight” rating on the stock in a research report on Wednesday, December 17th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Axon Enterprise in a research note on Monday, December 29th. The Goldman Sachs Group reduced their target price on shares of Axon Enterprise from $940.00 to $800.00 and set a “buy” rating on the stock in a research note on Wednesday, November 5th. Royal Bank Of Canada assumed coverage on shares of Axon Enterprise in a report on Monday, November 17th. They set an “outperform” rating and a $860.00 price target on the stock. Finally, TD Cowen reissued a “buy” rating on shares of Axon Enterprise in a research note on Wednesday, November 5th. Sixteen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $762.93.

Axon Enterprise Trading Up 5.8%

Shares of AXON opened at $550.19 on Wednesday. The stock has a market capitalization of $43.42 billion, a PE ratio of 361.97, a P/E/G ratio of 15.67 and a beta of 1.48. The company’s fifty day moving average is $538.95 and its 200 day moving average is $627.46. The company has a debt-to-equity ratio of 0.53, a quick ratio of 2.89 and a current ratio of 2.53. Axon Enterprise has a fifty-two week low of $396.41 and a fifty-two week high of $885.91.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $2.15 EPS for the quarter, topping analysts’ consensus estimates of $1.60 by $0.55. The business had revenue of $796.72 million during the quarter, compared to analysts’ expectations of $755.29 million. Axon Enterprise had a net margin of 4.48% and a return on equity of 2.82%. The business’s revenue was up 38.5% on a year-over-year basis. During the same period last year, the company posted $2.08 EPS. Sell-side analysts expect that Axon Enterprise will post 5.8 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Axon Enterprise news, President Joshua Isner sold 20,000 shares of the company’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $552.60, for a total value of $11,052,000.00. Following the transaction, the president directly owned 249,502 shares in the company, valued at $137,874,805.20. This represents a 7.42% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Jennifer H. Mak sold 1,134 shares of the firm’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $600.00, for a total transaction of $680,400.00. Following the transaction, the chief accounting officer directly owned 13,740 shares in the company, valued at approximately $8,244,000. This trade represents a 7.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 58,040 shares of company stock worth $32,251,738 over the last 90 days. Corporate insiders own 4.40% of the company’s stock.

Hedge Funds Weigh In On Axon Enterprise

Several institutional investors have recently made changes to their positions in the company. Brighton Jones LLC purchased a new position in Axon Enterprise during the 4th quarter valued at about $480,000. NewEdge Advisors LLC boosted its position in Axon Enterprise by 41.1% during the 1st quarter. NewEdge Advisors LLC now owns 2,294 shares of the biotechnology company’s stock valued at $1,207,000 after acquiring an additional 668 shares in the last quarter. Empowered Funds LLC boosted its position in Axon Enterprise by 8.4% during the 1st quarter. Empowered Funds LLC now owns 2,028 shares of the biotechnology company’s stock valued at $1,067,000 after acquiring an additional 157 shares in the last quarter. Woodline Partners LP increased its holdings in shares of Axon Enterprise by 40.6% in the 1st quarter. Woodline Partners LP now owns 6,932 shares of the biotechnology company’s stock valued at $3,646,000 after acquiring an additional 2,003 shares during the period. Finally, Sivia Capital Partners LLC bought a new position in shares of Axon Enterprise in the 2nd quarter worth $284,000. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Trending Headlines about Axon Enterprise

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Q4 results materially beat expectations — revenue +39% to ~$796.7M and non‑GAAP EPS $2.15 vs. consensus — and management reiterated aggressive growth targets and large contracted bookings, which drove investor optimism. Axon’s Q4 Earnings Top Estimates
• Positive Sentiment: Company highlighted AI adoption across its device + software platform (body cams, TASER 10, evidence management) and reported strong net revenue retention and bookings/backlog growth — messaging that the hardware‑to‑software flywheel reduces AI disruption risk and supports revenue expansion. Taser Maker Axon Says Its Business Is Being ‘Supercharged by AI.’
• Positive Sentiment: Market reaction: multiple outlets and analysts upgraded tone or reiterated buy cases based on the beat and 2026+ targets, lifting momentum after a prior steep selloff tied to SaaS/AI fears. Taser-maker Axon pops 18% as AI boosts demand
• Neutral Sentiment: Analyst price‑target revisions are mixed: several firms trimmed targets post‑report (Barclays, Morgan Stanley, Piper Sandler) but many maintain overweight/buy views — the market is re‑pricing near‑term risk while keeping upside scenarios. These Analysts Cut Their Forecasts On Axon
• Neutral Sentiment: Short-interest data in the feed appears anomalous (reporting 0 shares / NaN changes) and shows no meaningful days‑to‑cover signal — treat that data as unreliable for trading decisions today.
• Negative Sentiment: An insider transaction: CEO Patrick W. Smith sold 10,000 shares at ~$500.24 (filed with the SEC). The sale is small relative to total holdings but may be viewed negatively by some traders. SEC Form 4
• Negative Sentiment: Profitability caveat: several pieces note that while top‑line growth is accelerating, margins/profitability have not fully caught up — a risk if investors rotate to profitability metrics. Axon Stock Is On Fire, But Here’s the Bad News

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.